Table 1

Patient demographics and results

DialysisUlcer historyTotal
n150150300
Male (%)61 (40.7)62 (41.3)123 (41.0)
Race*
    White116 (77.3)64 (42.7)180 (60.0)
    Black20 (13.3)54 (36.0)74 (24.7)
    Hispanic11 (7.3)28 (18.6)39 (13.0)
    Other3 (2.0)4 (2.7)7 (2.3)
Age*64.9 ± 0.9874.25 ± 1.0470.22 ± 0.58
Type 2 diabetes (%)139 (92.6)138 (92.0)277 (92.3)
Amputation (%)*22 (14.7)5 (3.3)27 (9)
Ulceration (%)79 (52.7)79 (52.7)158 (52.6)
Neuropathy testing
    Semmes Weinstein monofilament40 (26.7)41 (27.3)81 (27)
    Vibration perception threshold4 (2.7)3 (2.0)7 (2.3)
    Other assessment5 (3.3)12 (8.0)17 (5.7)
    No neuropathy testing101 (67.3)94 (62.7)195 (65)
Vascular assessment
    Pedal pulse evaluated71 (47.3)84 (56.0)155 (51.7)
    Ankle-brachial index evaluated19 (12.7)13 (8.7)32 (10.7)
    No assessment60 (40.0)53 (35.3)113 (37.6)
Diabetes education
    Session 1 (n)1 (0.6)01 (0.3)
    Session 2 (n)1 (0.6)01 (0.3)
    Sessions 3–4000
Podiatry
    Podiatry (anytime)*74 (49.3)121 (80.6)195 (65)
    Podiatry before an ulcer*63 (42)27 (18)90 (30)
    Total podiatry visits296362658
Therapeutic shoes and insoles
    Received shoes or insoles11 (7.3)10 (6.6)21 (7.0)
    Received second shoes or insoles1 (0.6)3 (2.0)4 (1.3)
    Received third shoes or insoles000
  • Data are n (%) or means ± SE.

  • *P < 0.001.